Adenoid Cystic Carcinoma - Pipeline Insight, 2024

This “Adenoid Cystic Carcinoma- Pipeline Insight, 2024” report provides comprehensive insights about 50+ companies and 5+ pipeline drugs in Adenoid Cystic Carcinoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Adenoid Cystic Carcinoma: Understanding

Adenoid Cystic Carcinoma: Overview

Adenoid cystic carcinoma (ACC) is a relatively rare form of cancer that most commonly develops in the salivary glands or other regions of the head and neck. ACC can occur in other parts of the body, such as the breast, skin, cervix in females, prostate gland in males, and various other areas. ACC tumors are characterized by a distinctive histological pattern of abnormal “nests” or cords of certain cells (epithelial cells) that surround and/or infiltrate ducts or glandular structures within the affected organ. These structures are typically filled with a mucous-like material or contain abnormal fibrous membranes. Such characteristics are apparent during microscopic evaluation of tumor cells from a biopsy sample.

ACC is considered a low-grade malignancy that has a history of slow growth. Rarely, ACC can be aggressively invasive and infiltrate nearby lymph nodes as well as the “sheaths” or coatings surrounding nerve fibers (perineural spaces). This form of cancer may have a tendency to recur later at the site where it first developed (local recurrence) and in approximately 50% of patients, ACC spreads to distant bodily sites, particularly the lungs (metastatic disease), potentially resulting in life-threatening complications. ACC typically occurs during adulthood, around the ages of 40 to 60, but has also been diagnosed in children and adolescents.

Causes
The exact cause of adenoid cystic carcinoma is unknown. However, current research suggests that genetic changes (mutations) are the underlying basis of cellular malignant transformation in many cancers, including ACC.

Researchers speculate that a protein produced by the fusion of two transcription factor genes, MYB-NFIB, plays a role in the development of ACC tumors. This fusion protein is found in up to 90-95 % of ACC tumors. Mutations in the NOTCH1 gene are also associated with ACC, particularly in patients with recurrent or metastatic disease. Patients with NOTCH1 gene mutations have a worse prognosis.

Diagnosis
Radiological investigations like computerized tomography (CT) and magnetic resonance imaging (MRI) are the imaging modalities of choice to help delineate the extension of the primary tumor as well as for staging purposes. A biopsy of the tumor is needed for definitive diagnosis where the characteristic histological features along with the immunohistochemical markers like smooth muscle actin, S100, vimentin, as well as for MYB and CD 117 (c-kit) confirm the diagnosis.

Treatment and Management
Complete resection of the tumor via surgery, if possible, is the mainstay for treatment. For localized ACC of the head and neck, care is taken to avoid accidental severance of nerve tissue in the adjoining area and to ensure clear surgical margins. In patients with the spread of disease to the cervical lymph nodes, a modified radical neck dissection is the preferred route. However, despite good surgical techniques, the 5 to 10-year recurrence rate is roughly 75%. Surgically resectable cases with positive margins, perineural invasion, and positive lymph nodes carry a poor prognosis. Although there are no defined guidelines, most centers prefer patients to undergo postoperative radiation therapy in the presence of poor prognostic factors, as studies have shown that it can significantly lower the rate of local recurrence compared to surgical resection alone.

Whether postoperative radiation therapy leads to an overall increase in survival is still debatable as the evidence is confounded by the need for long-term follow-up as recurrence of malignancy is seen after 5 years in nearly 50% of the cases. Furthermore, radiation may prevent local recurrences, but patients may develop recurrences in distant sites outside the radiation field. Despite the lack of clarity in the data, patients with intermediate or high-grade ACC or any grade tumor with positive surgical margins are recommended to have postoperative radiation treatment to 60 Gy or more. Patients with an irresectable tumor are generally offered radiation therapy with or without systemic treatment but have poorer outcomes.

Adenoid Cystic Carcinoma- Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Adenoid Cystic Carcinoma pipeline landscape is provided which includes the disease overview and Adenoid Cystic Carcinoma treatment guidelines. The assessment part of the report embraces, in depth Adenoid Cystic Carcinoma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Adenoid Cystic Carcinoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Adenoid Cystic Carcinoma R&D. The therapies under development are focused on novel approaches to treat/improve Adenoid Cystic Carcinoma.

Adenoid Cystic Carcinoma Emerging Drugs Chapters

This segment of the Adenoid Cystic Carcinoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Adenoid Cystic Carcinoma Emerging Drugs

Rivoceranib : Elevar Therapeutics
Rivoceranib is the first small-molecule tyrosine kinase inhibitor to be approved in gastric cancer under the name Apatinib in China (December 2014). Rivoceranib is a highly potent inhibitor of vascular endothelial growth factor receptor 2 (VEGFR-2), the primary pathway for tumor angiogenesis. VEGFR-2 inhibition is a clinically validated approach to limit tumor growth and disease progression. Rivoceranib has been studied in over 1,000 patients worldwide and was well tolerated in clinical trials with a comparable safety profile to other TKIs. Rivoceranib is currently being studied as a monotherapy and in combination with chemotherapy and immunotherapy. Clinical studies are underway in multiple tumor types including, gastric cancer, hepatocellular carcinoma (combo w/camrelizumab), adenoid cystic carcinoma, and colorectal cancer (combo w/Lonsurf®). Orphan drug designations for rivoceranib have been granted in gastric cancer (U.S., EU, and South Korea) in adenoid cystic carcinoma (U.S.), and hepatocellular carcinoma (U.S.).

Osugacestat: Ayala Pharmaceuticals
Ayala Pharmaceuticals investigational lead candidate (AL-101) is a novel, injectable, potent and selective small molecule gamma secretase inhibitor (GSI). AL101 is currently being studied in 2 ongoing Phase 2 trials. The ACCURACY trial for the treatment of patients with recurrent/metastatic adenoid cystic carcinoma (R/M ACC), and our Phase 2 TENACITY trial for the treatment of patients with recurrent/metastatic triple negative breast cancer (R/M TNBC). The US Food and Drug Administration (FDA) granted Orphan Drug Designation and Fast Track Designation to AL101 for the potential treatment of ACC.

Adenoid Cystic Carcinoma: Therapeutic Assessment

This segment of the report provides insights about the different Adenoid Cystic Carcinoma drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Adenoid Cystic Carcinoma

There are approx. 5+ key companies which are developing the therapies for Adenoid Cystic Carcinoma. The companies which have their Adenoid Cystic Carcinoma drug candidates in the most advanced stage, i.e. phase III include, Deerland Probiotics & Enzymes.

Phases

This report covers around 50+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Adenoid Cystic Carcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Adenoid Cystic Carcinoma: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Adenoid Cystic Carcinoma therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Adenoid Cystic Carcinoma drugs.

Adenoid Cystic Carcinoma Report Insights

• Adenoid Cystic Carcinoma Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Adenoid Cystic Carcinoma Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Adenoid Cystic Carcinoma drugs?
• How many Adenoid Cystic Carcinoma drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Adenoid Cystic Carcinoma?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Adenoid Cystic Carcinoma therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Adenoid Cystic Carcinoma and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Ayala Pharmaceuticals
• CureVac
• Elevar Therapeutics
• Actuate Therapeutics
• Merck & Co.

Key Products

• AL101
• CV8102
• Rivoceranib
• 9-ING-41
• Pembrolizumab

This product will be delivered within 1-3 business days.